Abstract
Cognitive impairment is common in multiple sclerosis (MS), especially when assessed by neuropsychological tests that emphasize mental processing speed, episodic memory, and some aspects of executive function. In this Review, we question why some MS patients develop severe impairment in cognitive abilities, while cognitive ability remains intact in others. We find that the heterogeneity in neuropsychological presentation among patients with MS reflects the influence of many factors, including genetics, sex, intelligence, disease course, comorbid neuropsychiatric illness, and health behaviors. Neuropsychological deficits are also robustly correlated with brain MRI metrics. Male patients with early evidence of cerebral gray matter atrophy are most prone to impairment, whereas high premorbid intelligence improves the neuropsychological prognosis. Routine evaluation of cognition is useful for helping patients to navigate problems related to activities of daily living and work disability and, if reliable methods are employed, cognitive decline can be detected and included among the many clinical signs of disease progression or treatment failure. Pharmacological treatments for neuropsychological impairment are on the horizon, although presently no firm medical indications exist for the condition.
Key Points
-
Multiple sclerosis (MS) is both an inflammatory and neurodegenerative disease, with cognition affected in roughly 50% of patients
-
Cognitive impairment is most commonly detected on tests of mental processing speed and episodic memory
-
Neuropsychological testing is sensitive to MS cognitive disorder and can be applied in brief, routine evaluations
-
Male patients with low education or intelligence, early onset of MS, and evidence of cerebral gray matter atrophy seem most prone to impairment, whereas high premorbid intelligence is protective
-
To date, evidence for any particular medical therapy improving cognition in MS has been inconsistent, despite being an area of intense investigation
-
Future MS clinical trials should include cognitive outcome measures and use neuropsychological tests that are reliable and are known to reveal clinically meaningful changes
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hauser, S. L., Oksenberg, J. R., Hauser, S. L. & Oksenberg, J. R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52, 61–76 (2006).
Charcot, J. M. Lectures on the Diseases of the Nervous System (New Sydenham Society, London, 1877).
Rao, S. M., Leo, G. J., Bernardin, L. & Unverzagt, F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41, 685–691 (1991).
[No authors listed] Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43, 655–661 (1993).
Jacobs, L. D. et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exascerbating–remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult. Scler. 1, 118–135 (1995).
Johnson, K. P. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50, 701–708 (1998).
Amato, M. P., Zipoli, V. & Portaccio, E. Multiple-sclerosis related cognitive changes: a review of cross-sectional and longitudinal studies. J. Neurol. Sci. 245, 41–46 (2006).
Benedict, R. H. B. et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin. Neuropsychol. 16, 381–397 (2002).
Chiaravalloti, N. D. & DeLuca, J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 7, 1139–1151 (2008).
Patti, F. Cognitive impairment in multiple sclerosis. Mult. Scler. 15, 2–8 (2009).
Patti, F. et al. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult. Scler. 15, 779–788 (2009).
Benedict, R. H. B. et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J. Int. Neuropsychol. Soc. 12, 549–558 (2006).
Carone, D., Benedict, R. H. B., Munschauer, F. E. III, Fishman, I. & Weinstock-Guttman, B. Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J. Int. Neuropsychol. Soc. 11, 574–583 (2005).
Wechsler, D. Wechsler Adult Intelligence Scale, 4th edn (Pearson, New York, 2008).
Lezak, M. Neuropsychological Assessment (Oxford University Press, New York, 1995).
DeLuca, J., Chelune, G. J., Tulsky, D. S., Lengenfelder, J. & Chiaravalloti, N. D. Is speed of processing or working memory the primary information processing deficit in multiple sclerosis? J. Clin. Exp. Neuropsychol. 26, 550–562 (2004).
Archibald, C. J. & Fisk, J. D. Information processing efficiency in patients with multiple sclerosis. J. Clin. Exp. Neuropsychol. 22, 686–701 (2000).
Rao, S. M. On the nature of memory disturbance in multiple sclerosis. J. Clin. Exp. Neuropsychol. 11, 699–712 (1989).
DeLuca, J., Gaudino, E. A., Diamond, B. J., Christodoulou, C. & Engel, R. A. Acquisition and storage deficits in multiple sclerosis. J. Clin. Exp. Neuropsychol. 20, 376–390 (1998).
Kalmar, J. H., Gaudino, E. A., Moore, N. B., Halper, J. & Deluca, J. The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychology 22, 442–449 (2008).
Langdon, D. W. & Thompson, A. J. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mult. Scler. 5, 94–100 (1999).
Rao, S. M. et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41, 692–696 (1991).
Benedict, R. H. B. et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J. Neurol. Sci. 231, 29–34 (2005).
Buschke, F. & Fuld, P. A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24, 1019–1025 (1974).
Barbizet, J. & Cany, E. Clinical and psychometric study of a patient with memory disturbances. Int. J. Neurol. 7, 44–54 (1968).
Benton, A. L. & Hamsher, K. Multilingual Aphasia Examination (AJA Associates, Iowa City, 1989).
Borkowski, J. G., Benton, A. L. & Spreen, O. Word fluency and brain damage. Neuropsychologia 5, 135–140 (1967).
Gronwall, D. M. A. Paced auditory serial addition task: a measure of recovery from concussion. Percept. Mot. Skills 44, 367–373 (1977).
Rao, S. M. Neuropsychological Screening Battery for Multiple Sclerosis (National Multiple Sclerosis Society, New York, 1991).
Smith, A. Symbol Digit Modalities Test: Manual (Western Psychological Services, Los Angeles, 1982).
Huijbregts, S. C., Kalkers, N. F., de Sonneville, L. M., de Groot, V. & Polman, C. H. Cognitive impairment and decline in different MS subtypes. J. Neurol. Sci. 245, 187–194 (2006).
Christodoulou, C. et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology 60, 1793–1798 (2003).
Amato, M. P. et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63, 89–93 (2004).
Camp, S. J. et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain 128, 2891–2898 (2005).
Sepulcre, J. et al. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult. Scler. 12, 187–195 (2006).
Portaccio, E. et al. Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery. Mult. Scler. 16, 611–617 (2010).
Peyser, J. M., Rao, S. M., LaRocca, N. G. & Kaplan, E. Guidelines for neuropsychological research in multiple sclerosis. Arch. Neurol. 47, 94–97 (1990).
Benedict, R. H. B., Schretlen, D., Groninger, L., Dobraski, M. & Shpritz, B. Revision of the Brief Visuospatial Memory Test: studies of normal performance, reliability, and validity. Psychol. Assess. 8, 145–153 (1996).
Benedict, R. H. B. Brief Visuospatial Memory Test—Revised: Professional Manual (Psychological Assessment Resources, Odessa, FL, 1997).
Delis, D. C., Kramer, J. H., Kaplan, E. & Ober, B. A. California Verbal Learning Test Manual: Second Edition, Adult Version (Psychological Corporation, San Antonio, TX, 2000).
Delis, D. C., Kaplan, E. & Kramer, J. H. Delis–Kaplan Executive Function System (Psychological Corporation, San Antonio, TX, 2001).
Benton, A. L., Sivan, A. B., Hamsher, K., Varney, N. R. & Spreen, O. Contributions to Neuropsychological Assessment (Oxford University Press, New York, 1994).
Strober, L. et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult. Scler. 15, 1077–1084 (2009).
Duquin, J. A., Parmenter, B. A. & Benedict, R. H. B. Influence of recruitment and participation bias on neuropsychological research among MS patients. J. Int. Neuropsychol. Soc. 14, 494–498 (2008).
Parmenter, B. A. et al. Validity of the Wisconsin Card Sorting and Delis–Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J. Clin. Exp. Neuropsychol. 29, 215–223 (2007).
Benedict, R. H. B. Effects of using same vs alternate form memory tests in short-interval, repeated assessment in multiple sclerosis. J. Int. Neuropsychol. Soc. 11, 727–736 (2005).
Simon, J. H. et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 53, 139–148 (1999).
Camp, S. J. et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 122, 1341–1348 (1999).
Deloire, M. S. et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76, 519–526 (2005).
Huijbregts, S. C. et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 63, 335–339 (2004).
Nocentini, U., Giordano, A., Di Vincenzo, S., Panella, M. & Pasqualetti, P. The Symbol Digit Modalities Test—oral version: Italian normative data. Funct. Neurol. 21, 93–96 (2006).
Nocentini, U. et al. Cognitive dysfunction in patients with relapsing–remitting multiple sclerosis. Mult. Scler. 12, 77–87 (2006).
Parmenter, B. A., Testa, S. M., Schretlen, D. J., Weinstock-Guttman, B. & Benedict, R. H. The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J. Int. Neuropsychol. Soc. 16, 6–16 (2010).
Parmenter, B. A., Weinstock-Guttman, B., Garg, N., Munschauer, F. & Benedict, R. H. B. Screening for cognitive impairment in MS using the Symbol Digit Modalities Test. Mult. Scler. 13, 52–57 (2007).
Benedict, R. H. B. et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch. Neurol. 63, 1301–1306 (2006).
Bermel, R. A., Sharma, J., Tjoa, C. W., Puli, S. R. & Bakshi, R. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J. Neurol. Sci. 208, 57–65 (2003).
Benedict, R. H., Ramasamy, D., Munschauer, F., Weinstock-Guttman, B. & Zivadinov, R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J. Neurol. Neurosurg. Psychiatry 80, 201–206 (2009).
Tekok-Kilic, A. et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage 36, 1294–1300 (2007).
Benedict, R. H. B. et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult. Scler. 13, 722–730 (2007).
Benedict, R. H. B. et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am. J. Neuroradiol. 26, 1824–1831 (2005).
Benedict, R. H. B., Carone, D. & Bakshi, R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J. Neuroimaging 14 (Suppl. 3), 36S–45S (2004).
Benedict, R. H. B. et al. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch. Neurol. 61, 226–230 (2004).
Drake, A. S. et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult. Scler. 16, 228–237 (2010).
Fischer, J. S., Rudick, R. A., Cutter, G. R. & Reingold, S. C. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 5, 244–250 (1999).
Rosti, E., Hamalainen, P., Koivisto, K. & Hokkanen, L. PASAT in detecting cognitive impairment in relapsing–remitting MS. Appl. Neuropsychol. 14, 101–112 (2007).
Bever, C., Grattan, L., Panitch, H. S. & Johnson, K. P. The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study. Mult. Scler. 1, 165–169 (1995).
Benedict, R. H. B. et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult. Scler. 14, 940–946 (2008).
Morrow, S. A. et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult. Scler. 16, 1385–1392 (2010).
Morrow, S. A., Jurgensen, S., Forrestal, F. & Benedict, R. H. B. Effects of acute relapses on neuropsychological status in multiple sclerosis patients. J. Neurol. doi:10.1007/s00415-011-5975-5973.
Morrow, S. A. et al. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clinical Neuropsychologist 24, 1131–1145 (2010).
Bodling, A. M., Denney, D. R. & Lynch, S. G. Cognitive aging in patients with multiple sclerosis: a cross-sectional analysis of speeded processing. Arch. Clin. Neuropsychol. 24, 761–767 (2009).
Amato, M. P., Ponziani, G., Siracusa, G. & Sorbi, S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch. Neurol. 58, 1602–1606 (2001).
Amato, M. P. et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology 75, 1134–1140 (2010).
Beatty, W. W. & Aupperle, R. L. Sex differences in cognitive impairment in multiple sclerosis. Clin. Neuropsychol. 16, 472–480 (2002).
Savettieri, G. et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J. Neurol. 251, 1208–1214 (2004).
Marrie, R. A., Cutter, G., Tyry, T., Vollmer, T. & Campagnolo, D. Does multiple sclerosis-associated disability differ between races? Neurology 66, 1235–1240 (1235).
Arnett, P. A., Barwick, F. H. & Beeney, J. E. Depression in multiple sclerosis: review and theoretical proposal. J. Int. Neuropsychol. Soc. 14, 691–724 (2008).
Morrow, S. A., Weinstock-Guttman, B., Munschauer, F., Hojnacki, D. & Benedict, R. H. B. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Mult. Scler. 15, 998–1005 (2009).
Amato, M. P. et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J. Neurol. 253, 1054–1059 (2006).
Glanz, B. I. et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult. Scler. 13, 1004–1010 (2007).
Comi, G. et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J. Neurol. Sci. 132, 222–227 (1995).
Filippi, M. et al. Influence of clinical variables on neuropsychological performance in multiple sclerosis. Eur. Neurol. 34, 324–328 (1994).
Fisher, E., Lee, J. C., Nakamura, K. & Rudick, R. A. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 64, 255–265 (2008).
Hawkes, C. H. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult. Scler. 13, 610–615 (2007).
Pittas, F. et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J. Neurol. 256, 577–585 (2009).
Staff, N. P., Lucchinetti, C. F. & Keegan, B. M. Multiple sclerosis with predominant, severe cognitive impairment. Arch. Neurol. 66, 1139–1143 (2009).
Ghaffar, O. & Feinstein, A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 71, 164–169 (2008).
Messinis, L., Kyprianidou, A., Malefaki, S. & Papathanasopoulos, P. Neuropsychological deficits in long-term frequent cannabis users. Neurology 66, 737–739 (2006).
Chapman, B. P., Lyness, J. M. & Duberstein, P. Personality and medical illness burden among older adults in primary care. Psychosom. Med. 69, 277–282 (2007).
Schwartz, E. S., Chapman, B. P., Duberstein, P. R., Weinstock-Guttman, B. & Benedict, R. H. The NEO-FFI in multiple sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. Assessment 18, 39–49 (2011).
Benedict, R. H. B. et al. Cortical atrophy and personality in multiple sclerosis. Neuropsychology 22, 432–441 (2008).
Mahley, R. W. & Rall, S. C. Jr. Apolipoprotein E: far more than a lipid transport protein. Annu.Rev. Genomics Hum. Genet. 1, 507–537 (2000).
Enzinger, C. et al. Accelerated evolution of brain atrophy and “black holes” in MS patients with APOE-ε4. Ann. Neurol. 55, 563–569 (2004).
De Stefano, N. et al. Influence of apolipoprotein E ε4 genotype on brain tissue integrity in relapsing–remitting multiple sclerosis. Arch. Neurol. 61, 536–540 (2004).
Horáková, D. et al. APOE ε4-positive multiple sclerosis patients develop more gray matter and whole brain atrophy. a 4-year longitudinal study using the 15-year disease onset model. Fol. Biol. Praha 56, 242–251 (2010).
Ghaffar, O. & Feinstein, A. APOE ε4 and cognitive dysfunction in multiple sclerosis: a review. J. Neuropsychiatry Clin. Neurosci. 22, 155–165 (2010).
Oliveri, R. L. et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol. Scand. 100, 290–295 (1999).
Koutsis, G. et al. An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis. Mult. Scler. 15, 174–179 (2009).
Koutsis, G. et al. APOE ε4 is associated with impaired verbal learning in patients with MS. Neurology 68, 546–549 (2007).
Parmenter, B. A., Denney, D. R., Lynch, S. G., Middleton, L. S. & Harlan, L. M. Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms. Mult. Scler. 13, 25–32 (2007).
Savettieri, G. et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J. Neurol. 251, 1208–1214 (2004).
Ghaffar, O., Reis, M., Pennell, N., O'Connor, P. & Feinstein, A. APOE ε4 and the cognitive genetics of multiple sclerosis. Neurology 74, 1611–1618 (2010).
Portaccio, E. et al. ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. Acta Neurol. Scand. 120, 439–441 (2009).
van der Walt, A. et al. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 73, 1018–1025 (2009).
Jensen, C. J. et al. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS ONE 5, e10003 (2010).
Zivadinov, R. et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain derived neurotrophic factor (BDNF). Hum. Mol. Genet. 16, 2659–2668 (2007).
Weinstock-Guttman, B. et al. The rs2030324 SNP of brain derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology 18, 43–52 (2010).
Cerasa, A. et al. The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: an imaging genetic study. Behav. Brain Res. 207, 377–386 (2010).
Oksenberg, J. R., Baranzini, S. E., Sawcer, S. & Hauser, S. L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9, 516–526 (2008).
Fazekas, F. et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53, 448–456 (1999).
Bakshi, R., Caruthers, S. D., Janardhan, V. & Wasay, M. Intraventricular CSF pulsation artifact on fast fluid-attenuated inversion-recovery MR images: analysis of 100 consecutive normal studies. AJNR Am. J. Neuroradiol. 21, 503–508 (2000).
Bakshi, R., Ariyaratana, S., Benedict, R. H. & Jacobs, L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch. Neurol. 58, 742–748 (2001).
Truyen, L. et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 47, 1469–1476 (1996).
Zivadinov, R. & Bakshi, R. Role of MRI in multiple sclerosis I: inflammation and lesions. Front. Biosci. 9, 665–683 (2004).
Rao, S. M., Leo, G. J., Haughton, V. M., Aubin-Faubert, P. S. & Bernardin, L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 39, 161–166 (1989).
Geurts, J. J. et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 236, 254–260 (2005).
Geurts, J. J. et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am. J. Neuroradiol. 26, 572–527 (2005).
Bagnato, F. et al. T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis. Mult. Scler. 16, 1203–1212 (2010).
Roosendaal, S. D. et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult. Scler. 15, 708–714 (2009).
McDonald, W. I., Miller, D. H. & Barnes, D. The pathological evolution of multiple sclerosis. Neuropathol. Appl. Neurobiol. 18, 319–334 (1992).
Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).
Trapp, B. D., Ransohoff, R. & Rudick, R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295–302 (1999).
Peterson, J. W., Bö, L., Mörk, S., Chang, A. & Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389–400 (2001).
van Buchem, M. A. et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology 50, 1609–1617 (1998).
Comi, G. et al. Clinical, neurophysiological, and magnetic resonance imaging correlations in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64 (Suppl. 1), S21–S25 (1998).
Filippi, M. et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 68, 157–161 (2000).
Rovaris, M. et al. Cognitive dysfunction in patients with mildly disabling relapsing–remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J. Neurol. Sci. 195, 103–109 (2002).
Rudick, R. A., Fisher, E., Lee, J. C., Simon, J. & Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53, 1698–1704 (1999).
Hohol, M. J. et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch. Neurol. 54, 1018–1025 (1997).
Houtchens, M. K. et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 69, 113–123 (2007).
Benedict, R. H. B. et al. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J. Neuropsychiatry Clin. Neurosci. 14, 44–51 (2002).
Anderson, V. M. et al. Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study. Mult. Scler. 16, 1083–1090 (2010).
Sicotte, N. L. et al. Regional hippocampal atrophy in multiple sclerosis. Brain 131, 1134–1141 (2008).
Feinstein, A. et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62, 586–590 (2004).
Stern, Y. et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 271, 1004–1010 (1994).
Stern, Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, S69–S74 (2006).
Mainero, C. et al. fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage 21, 858–867 (2004).
Chiaravalloti, N. et al. Cerebral activation patterns during working memory performance in multiple sclerosis using fMRI. J. Clin. Exp. Neuropsychol. 27, 33–54 (2005).
Sumowski, J. F., Chiaravalloti, N., Wylie, G. & Deluca, J. Cognitive reserve moderates the negative effect of brain atrophy on cognitive effi ciency in multiple sclerosis. J. Int. Neuropsychol. Soc. 15, 606–612 (2009).
Sumowski, J. F., Wylie, G. R., Gonnella, A., Chiaravalloti, N. & Deluca, J. Premorbid cognitive leisure independently contributes to cognitive reserve in multiple sclerosis. Neurology 75, 1428–1431 (2010).
Sumowski, J. F., Wylie, G. R., Deluca, J. & Chiaravalloti, N. Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain 133, 362–374 (2010).
O'Brien, A. R., Chiaravalloti, N., Goverover, Y. & Deluca, J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch. Phys. Med. Rehabil. 89, 761–769 (2008).
Chiaravalloti, N. D., DeLuca, J., Moore, N. B. & Ricker, J. H. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult. Scler. 11, 58–68 (2005).
Waxman, S. G. Membranes, myelin, and the pathophysiology of multiple sclerosis. N. Engl. J. Med. 306, 1529–1533 (1982).
Bever, C. T. Jr et al. Treatment with oral 3, 4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47, 1457–1462 (1996).
Bever, C. T. Jr et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44, 1054–1059 (1994).
Rossini, P. M. et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler. 7, 354–358 (2001).
Geisler, M. W. et al. The effects of amantadine and pemoline on cognitive funcitoning in multiple sclerosis. Arch. Neurol. 53, 185–188 (1996).
Wilken, J. A. et al. Treatment of multiple sclerosis related cognitive problems with adjunctive modafinil: Rationale and preliminary supportive data. Int. J. MS Care 10, 1–10 (2008).
Harel, Y., Appleboim, N., Lavie, M. & Achiron, A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J. Neurol. Sci. 276, 38–40 (2009).
Benedict, R. H. et al. Effects of L-amphetamine sulfate on cognitive function in multiple sclerosis patients. J. Neurol. 255, 848–852 (2008).
Morrow, S. A. et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J. Neurol. 256, 1095–1102 (2009).
Krupp, L. B. et al. Donepezil improves memory in multiple sclerosis in a randomized clinical trial. Neurology 63, 1579–1585 (2004).
Krupp, L. et al. A multi-center randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology (in press).
Shaygannejad, V., Janghorbani, M., Ashtari, F., Zanjani, H. A. & Zakizade, N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can. J. Neurol. Sci. 35, 476–481 (2008).
Sumoski, J. F. et al. L-amphetamine improves memory in MS patients with objective memory impairment. Mult. Scler. (in press).
Benedict, R. & Bobholz, J. Multiple sclerosis. Semin. Neurol. 27, 78–86 (2007).
Chapman, B. P., Duberstein, P. & Lyness, J. M. The distressed personality type: replicability and general health associations. Eur. J. Personality (2007).
Smits, R. C. et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44, 1701–1705 (1994).
Author information
Authors and Affiliations
Contributions
R. H. B. Benedict and R. Zivadinov contributed equally to researching, discussing, writing, reviewing and editing this article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Benedict, R., Zivadinov, R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7, 332–342 (2011). https://doi.org/10.1038/nrneurol.2011.61
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.61
This article is cited by
-
Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time
Journal of Neurology (2024)
-
Brain MRI disease burden and sex differences in cognitive performance of patients with multiple sclerosis
Acta Neurologica Belgica (2024)
-
Comparing the effect of in water vs. land vs. combined land–water training on functional mobility and balance in women with multiple sclerosis: a Burdenko method
Sport Sciences for Health (2024)
-
P300 event-related potentials in patients with multiple sclerosis
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2023)
-
Disease severity classification using passively collected smartphone-based keystroke dynamics within multiple sclerosis
Scientific Reports (2023)